Coherus Oncology (CHRS) Debt/Equity Ratio: History & Chart

Coherus Oncology, Inc.(CHRS)

Biotechnology · Redwood City, CA

$1.11-0.01 (-1.27%)

Delayed quote: Oct 6, 2026, 9:45 AM EDT

About Coherus Oncology, Inc.

Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust pipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.

Redwood City, CA

144 employees

www.coherus.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Dennis Lanfear

View full financials

CHRS Debt to Equity Ratio Metrics

DEBT TO EQUITY RATIO

0.62

DEBT TO EQUITY RATIO AVG TTM

0.56

DEBT TO EQUITY RATIO AVG 3Y

-1.70

DEBT TO EQUITY RATIO AVG 5Y

-1.20

DEBT TO EQUITY RATIO AVG 10Y

0.28

DEBT TO EQUITY RATIO AVG 15Y

N/A

DEBT TO EQUITY RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

+11.53%

CURRENT VS 3Y AVG

+136.55%

CURRENT VS 5Y AVG

+151.73%

CURRENT VS 10Y AVG

+123.08%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

SECTOR MEDIAN · HEALTHCARE

0.14

median of 480 covered companies

CURRENT VS SECTOR MEDIAN

+342.70%

vs the sector median at left

NAME	MARKET CAP	DEBT TO EQUITY RATIO	TTM	3Y	5Y
Coherus Oncology, Inc. (CHRS)	$170.85M	0.62	0.56	-1.70	-1.20
Compass Therapeutics, Inc. (CMPX)vs ›	$172.06M	0.06	0.05	0.03	0.07
Precision BioSciences, Inc. (DTIL)vs ›	$173.06M	0.62	0.42	0.73	0.54
Cue Biopharma, Inc. (CUE)vs ›	$178.11M	3.81	0.34	0.34	0.27
Canton Strategic Holdings Inc (CNTN)vs ›	$179.67M	0.00	0.00	0.00	0.00
Inogen, Inc. (INGN)vs ›	$161.12M	0.09	0.10	0.10	0.08
ALX Oncology Holdings Inc. (ALXO)vs ›	$158.78M	0.07	0.17	0.12	0.08
Journey Medical Corporation (DERM)vs ›	$183.85M	0.80	1.04	1.07	0.91
Anavex Life Sciences Corp. (AVXL)vs ›	$155.69M	0.00	0.00	0.00	0.00
LifeMD, Inc. (LFMDP)vs ›	$154.72M	0.76	0.27	2.83	1.63

NAME

MARKET CAP

DEBT TO EQUITY RATIO

TTM

Coherus Oncology, Inc. (CHRS)

$170.85M

0.62

0.56

-1.70

-1.20

Compass Therapeutics, Inc. (CMPX)vs ›

$172.06M

0.06

0.05

0.03

0.07

Precision BioSciences, Inc. (DTIL)vs ›

$173.06M

0.62

0.42

0.73

0.54

Cue Biopharma, Inc. (CUE)vs ›

$178.11M

3.81

0.34

0.27

Canton Strategic Holdings Inc (CNTN)vs ›

$179.67M

0.00

Inogen, Inc. (INGN)vs ›

$161.12M

0.09

0.10

0.08

ALX Oncology Holdings Inc. (ALXO)vs ›

$158.78M

0.07

0.17

0.12

0.08

Journey Medical Corporation (DERM)vs ›

$183.85M

0.80

1.04

1.07

0.91

Anavex Life Sciences Corp. (AVXL)vs ›

$155.69M

0.00

LifeMD, Inc. (LFMDP)vs ›

$154.72M

0.76

0.27

2.83

1.63

Debt to Equity Ratio FAQ

What is the debt to equity ratio for Coherus Oncology, Inc. (CHRS)?

The debt to equity ratio for CHRS stock is 0.62.

Is Coherus Oncology, Inc.'s debt to equity ratio high or low?

The debt to equity ratio of 0.62 is 152% above its 5-year average of -1.20, around the middle of its 5-year range (-19.08–34.25).

What is the TTM average debt to equity ratio for Coherus Oncology, Inc. (CHRS)?

The TTM average debt to equity ratio for CHRS stock is 0.56.

What is the 3Y average debt to equity ratio for Coherus Oncology, Inc. (CHRS)?

The 3Y average debt to equity ratio for CHRS stock is -1.70.

What is the 5Y average debt to equity ratio for Coherus Oncology, Inc. (CHRS)?

The 5Y average debt to equity ratio for CHRS stock is -1.20.

What is the 10Y average debt to equity ratio for Coherus Oncology, Inc. (CHRS)?

The 10Y average debt to equity ratio for CHRS stock is 0.28.

DATE	DEBT TO EQUITY RATIO
2026-06-30	0.62
2026-03-31	0.69
2025-12-31	0.66
2025-09-30	0.46
2025-06-30	0.34
2025-03-31	-1.47
2024-12-31	-2.04
2024-09-30	-3.07
2024-06-30	-3.55
2024-03-31	-5.88
2023-12-31	-2.49
2023-09-30	-3.58
2023-06-30	-2.74
2023-03-31	-2.44
2022-12-31	-3.50
2022-09-30	-4.95
2022-06-30	-19.08
2022-03-31	34.25
2021-12-31	4.29
2021-09-30	3.20
2021-06-30	2.68
2021-03-31	3.27
2020-12-31	1.48
2020-09-30	1.62
2020-06-30	1.94
2020-03-31	1.21
2019-12-31	1.79
2019-09-30	3.17
2019-06-30	-44.46
2019-03-31	-4.81
2018-12-31	-2.67
2018-09-30	8.29
2018-06-30	1.62
2018-03-31	-56.84
2017-12-31	3.32
2017-09-30	1.80
2017-06-30	3.14
2017-03-31	1.29
2016-12-31	5.18
2016-09-30	3.04
2016-06-30	-1.64
2016-03-31	-1.50
2015-12-31	0.00
2015-09-30	0.00
2015-06-30	0.00
2015-03-31	0.00
2014-12-31	0.00
2014-09-30	0.25
2014-06-30	0.11
2014-03-31	-0.11
2013-12-31	-0.10
2013-09-30	0.00
2013-06-30	0.00
2013-03-31	0.00

DATE

DEBT TO EQUITY RATIO

2026-06-30

0.62

2026-03-31

0.69

2025-12-31

0.66

2025-09-30

0.46

2025-06-30

0.34

2025-03-31

-1.47

2024-12-31

-2.04

2024-09-30

-3.07

2024-06-30

-3.55

2024-03-31

-5.88

2023-12-31

-2.49

2023-09-30

-3.58

2023-06-30

-2.74

2023-03-31

-2.44

2022-12-31

-3.50

2022-09-30

-4.95

2022-06-30

-19.08

2022-03-31

34.25

2021-12-31

4.29

2021-09-30

3.20

2021-06-30

2.68

2021-03-31

3.27

2020-12-31

1.48

2020-09-30

1.62

2020-06-30

1.94

2020-03-31

1.21

2019-12-31

1.79

2019-09-30

3.17

2019-06-30

-44.46

2019-03-31

-4.81

2018-12-31

-2.67

2018-09-30

8.29

2018-06-30

1.62

2018-03-31

-56.84

2017-12-31

3.32

2017-09-30

1.80

2017-06-30

3.14

2017-03-31

1.29

2016-12-31

5.18

2016-09-30

3.04

2016-06-30

-1.64

2016-03-31

-1.50

2015-12-31

0.00

2015-09-30

0.00

2015-06-30

0.00

2015-03-31

0.00

2014-12-31

0.00

2014-09-30

0.25

2014-06-30

0.11

2014-03-31

-0.11

2013-12-31

-0.10

2013-09-30

0.00

2013-06-30

0.00

2013-03-31

0.00

Debt to Equity Ratio: 0.62

CHRS Debt to Equity Ratio

CHRS Average Debt to Equity Ratio Chart

CHRS Current vs Average Debt to Equity Ratio Chart

CHRS Debt to Equity Ratio Metrics

CHRS Competitors' Debt to Equity Ratio

Financial Health

Debt to Equity Ratio Formula & Definition

Debt to Equity Ratio FAQ

CHRS Debt to Equity Ratio History

Related Metrics